Tumour Registry Breast Cancer
This trial is active, not recruiting.
|Collaborator||Arbeitskreis Klinische Studien|
|Start date||February 2007|
|End date||June 2019|
|Trial size||4500 participants|
|Trial identifier||NCT01351584, IOM TMK, Tumorregister Mammakarzinom|
The registry aims to collect and analyse information on the antineoplastic treatment of breast cancer in daily routine practice of office-based and clinic-based medical oncologists in Germany.
Course of Antineoplastic Treatment
time frame: 5 years
Female participants at least 18 years old.
- Breast cancer
- 18 years and older
- Antineoplastic or antihormonal treatment
- No breast cancer
- Below 18 years
- No antineoplastic or antihormonal treatment
|Official title||Clinical Registry to Present Treatment and Sequences of Treatments in Routine Practice in Germany|
|Description||The TMK is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of breast cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. The impact of nutrition (MaNut) and physical activity (MaNut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (MaTox) and the multiple patient-reported outcomes (MaLife).|
Call for more information